Emergent BioSolutions Inc. — Director's Dealing 2019

Mar 21, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Emergent BioSolutions Inc. (EBS)
CIK: 0001367644
Period of Report: 2019-03-19

Reporting Person: Mulligan Seamus (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2019-03-19	Common Stock	A	7569	—	Acquired	56141	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	545590	Indirect

Footnotes

F1: These restricted stock units vest in three equal annual installments beginning on the day prior to the first anniversary of the date of grant, assuming continued service with the company. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement.

F2: Mr. Mulligan and his family, collectively hold an aggregate 100% equity interest in Nerano Pharma Ltd, which in turn is the direct owner of 545,590 shares of the Issuer's common stock.